Lv32
270 积分 2024-05-30 加入
FXR agonists in NASH treatment
1小时前
待确认
FXR-targeted drug discovery: Recent advances and therapeutic perspectives
1小时前
已完结
FXR agonists for NASH: How are they different and what difference do they make?
2小时前
已完结
Recent advances on FXR-targeting therapeutics
3小时前
已完结
Nicotinamide riboside, a trace nutrient in foods, is a Vitamin B3 with effects on energy metabolism and neuroprotection
1天前
已完结
Steatotic liver disease
8天前
已完结
Assessment of endocrine disruptor impacts on lipid metabolism in a fatty acid-supplemented HepaRG human hepatic cell line
3个月前
已完结
Alterations in male reproductive hormones in relation to environmental DDT exposure
4个月前
已完结
Sarmentol H derived from Sedum sarmentosum Bunge directly targets FXR to mitigate cholestasis by recruiting SRC-1
5个月前
已完结
Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation
6个月前
已完结
皖公网安备34019202002308
